Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COX-2 Use Should Be Limited, FDA Advisory Cmte. Member Furberg Says In NEJM

This article was originally published in The Pink Sheet Daily

Executive Summary

Drug Safety & Risk Management Committee member Furberg advocates using lowest effective dose for short-term use when a COX-2 inhibitor is needed. Furberg's editorial in the New England Journal of Medicine was released on the eve of the COX-2 advisory committee meeting.

You may also be interested in...



FDA's Woodcock To Testify Before Senate Health Committee March 3

Janet Woodcock is one of two FDA representatives testifying at two days of hearings on issues related to drug safety; Sandra Kweder will testify March 1. Vertex Pharmaceuticals CEO Joshua Boger will present the pharmaceutical industry's point of view.

FDA's Woodcock To Testify Before Senate Health Committee March 3

Janet Woodcock is one of two FDA representatives testifying at two days of hearings on issues related to drug safety; Sandra Kweder will testify March 1. Vertex Pharmaceuticals CEO Joshua Boger will present the pharmaceutical industry's point of view.

Safety Studies Should Be Required To Retain Celebrex, Bextra Approval – Researcher

Revised approval standards for COX-2 inhibitors still in development should be extended to marketed drugs "as a condition of their retention of approval," Penn researcher FitzGerald tells FDA advisory committee. FitzGerald says Vioxx safety signal is a class effect, calls Pfizer's argument that it is restricted to rofecoxib an "off-target fantasy."

Related Content

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel